Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and s 1033

quinazolines has been researched along with s 1033 in 19 studies

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (5.26)29.6817
2010's17 (89.47)24.3611
2020's1 (5.26)2.80

Authors

AuthorsStudies
Gelderblom, H; Guchelaar, HJ; van Erp, NP1
Geoerger, B; Leblond, P1
Beijnen, JH; Harmsen, S; Maas-Bakker, RF; Meijerman, I; Schellens, JH1
Andriamanana, I; Duretz, B; Gana, I; Hulin, A1
Robert, C; Sibaud, V1
Bacus, S; Brown, AM; Doherty, KR; Kramer, JW; Moran, DM; Shell, SA; Talbert, DR; Trusk, PB; Wappel, RL1
Ambudkar, SV; Cheng, HW; Hsiao, SH; Huang, YH; Li, YQ; Luo, SY; Sim, HM; Tuo, WC; Wu, CP1
Ashby, CR; Chen, ZS; Kathawala, RJ; Wang, YJ1
Ding, JF; Zhong, DF1
Ambudkar, SV; Bakhsheshian, J; Chang, KE; Gottesman, MM; Hall, MD; Shukla, S; Simpson, RM; Wei, BR1
Nakano, Y; Saita, T; Shin, M; Yamamoto, Y1
Broutin, S; Gil, S; Jovelet, C; Mir, O; Paci, A1
Adam, T; Bouchalová, K; Faber, E; Friedecký, D; Janečková, H; Mičová, K; Vrobel, I1
Ohyashiki, K; Okabe, S; Sakuta, J; Tanaka, Y; Tauchi, T1
Aderhold, C; Birk, R; Hock, C; Hörmann, K; Kramer, B; Kuhlin, B; Lammert, A; Schultz, JD1
Abbadi, S; Blakeley, JO; Bonne, N; Brem, H; Giovannini, M; Itzoe, M; Paldor, I; Rodriguez, FJ; Rowshanshad, D; Tyler, BM; Vigilar, V; Ye, X1
Usui, N1
Almeida, VH; Berzoti-Coelho, MG; Borges, CS; Cacemiro, MDC; Castro, FA; Ferreira, AF; Figueiredo-Pontes, LL; Gomes, FG; Monteiro, RQ; Nunes, NS; Simões, BP1
Cui, X; Li, C; Ma, J; Qiu, S; Shi, C; Sun, J; Xu, Y1

Reviews

6 review(s) available for quinazolines and s 1033

ArticleYear
Clinical pharmacokinetics of tyrosine kinase inhibitors.
    Cancer treatment reviews, 2009, Volume: 35, Issue:8

    Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution

2009
[Indications and current development of new targeted therapies in pediatric oncology].
    Bulletin du cancer, 2011, Volume: 98, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases

2011
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
    Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles

2013
Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.
    Chinese journal of cancer, 2014, Volume: 33, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Benzylisoquinolines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Imidazoles; Lapatinib; Multidrug Resistance-Associated Proteins; Piperazines; Purines; Pyrimidines; Quinazolines; Sildenafil Citrate; Sulfonamides; Sulfones; Taxoids; Triazines; Vardenafil Dihydrochloride

2014
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2013, Volume: 48, Issue:7

    Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib

2013
[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].
    Bulletin du cancer, 2016, Volume: 103, Issue:5

    Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Maternal Age; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk

2016

Other Studies

13 other study(ies) available for quinazolines and s 1033

ArticleYear
PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2013, Mar-12, Volume: 48, Issue:4-5

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Pregnane X Receptor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Steroid; Sorafenib

2013
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, May-01, Volume: 926

    Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles

2013
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
    Toxicology and applied pharmacology, 2013, Oct-01, Volume: 272, Issue:1

    Topics: Caspase 3; Caspase 7; Cell Survival; Cells, Cultured; Cholesterol; Crizotinib; Enzyme Activation; ERG1 Potassium Channel; Erlotinib Hydrochloride; Ether-A-Go-Go Potassium Channels; Humans; Indoles; Ion Channels; Lipids; Myocytes, Cardiac; Patch-Clamp Techniques; Pluripotent Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA; Sunitinib

2013
Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
    Biochemical pharmacology, 2013, Oct-01, Volume: 86, Issue:7

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Cycle Proteins; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; Lapatinib; Mice; Neoplasm Proteins; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrimidines; Quinazolines

2013
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Dec-17, Volume: 110, Issue:51

    Topics: 3T3 Cells; Adenosine; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Cell Line, Tumor; Diketopiperazines; Endothelial Cells; Firefly Luciferin; Gefitinib; Gene Expression; HEK293 Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Luciferases, Firefly; Luminescent Agents; Luminescent Measurements; Mice; Mice, Transgenic; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Xenobiotics

2013
Preparation of Antibodies and Development of an Enzyme-Linked Immunosorbent Assay for the Tyrosine Kinase Inhibitors Lapatinib and Nilotinib.
    Biological & pharmaceutical bulletin, 2015, Volume: 38, Issue:10

    Topics: Animals; Antibodies; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Female; Horseradish Peroxidase; Humans; Lapatinib; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rabbits; Rats, Wistar

2015
Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma.
    Therapeutic drug monitoring, 2016, Volume: 38, Issue:4

    Topics: Calibration; Chromatography, Liquid; Drug Monitoring; Humans; Imatinib Mesylate; Lapatinib; Plasma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry

2016
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
    Oncotarget, 2016, Aug-16, Volume: 7, Issue:33

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasms, Experimental; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines

2016
Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.
    Anticancer research, 2017, Volume: 37, Issue:6

    Topics: Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines

2017
The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.
    Journal of neuro-oncology, 2017, Volume: 135, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Everolimus; Lapatinib; Mice; Mice, Nude; Mice, Transgenic; Models, Statistical; Neoplasm Transplantation; Neurilemmoma; Neurofibromatosis 2; Peripheral Nervous System Neoplasms; Pyrimidines; Quinazolines; Sciatic Nerve; Time Factors

2017
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
    International journal of hematology, 2017, Volume: 106, Issue:5

    Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imidazoles; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Nitriles; Phlebotomy; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; Quinolines; Risk

2017
Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.
    Experimental hematology, 2018, Volume: 66

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Chromones; Disease Progression; Dose-Response Relationship, Drug; Female; Flavonoids; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morpholines; Myeloid Cells; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptor, PAR-1; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A

2018
Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis.
    Toxicology letters, 2022, Jul-15, Volume: 365

    Topics: Arrhythmias, Cardiac; Down-Regulation; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines

2022